Kineman R D, Teixeira L T, Amargo G V, Coschigano K T, Kopchick J J, Frohman L A
Department of Medicine, University of Illinois, Chicago, Illinois 60612, USA.
Endocrinology. 2001 Sep;142(9):3764-73. doi: 10.1210/endo.142.9.8382.
Excessive GHRH stimulation leads to somatotrope hyperplasia and, ultimately, pituitary adenoma formation in the metallothionein promoter-driven human GHRH (hGHRH) transgenic mouse. This pituitary phenotype is similar to that observed in humans with ectopic production of GHRH. In both mice and man, GHRH hyperstimulation also results in dramatic increases in circulating GH and IGF-I. To determine whether GH/IGF-I modulates the development and growth rate of GHRH-induced pituitary tumors, pituitary growth and histology were evaluated in mice generated from cross-breeding metallothionein promoter-driven hGHRH transgenic mice with GH receptor binding protein (GHR) gene disrupted mice (GHR(-/-)). Expression of the hGHRH transgene in 2-month-old GHR intact (GHR(+)) mice resulted in the doubling of pituitary weight that was largely attributed to an increase in the number of GH-immunopositive cells. Pituitary weight of GHR(+) hGHRH mice did not significantly change between 2 and 6 months of age, whereas at 12 months, weights increased up to 100-fold those of GHR(+) pituitaries, and 70% of the glands contained grossly visible adenomas. All adenomas stained positively for GH, whereas some showed scattered PRL staining. Pituitaries of GHR(-/-) mice were half the size of those of GHR(+) mice. Although reduced in size, the histological features of GHR(-/-) mouse pituitaries were suggestive of somatotrope hyperplasia. Despite evidence of somatotrope hyperplasia, pituitaries from GHR(-/-) mice as old as 28 months of age were similar in size to those of 2-month-old mice and did not show signs of adenoma formation. Expression of the hGHRH transgene in GHR(-/-) mice did not significantly increase pituitary size between 2 and 6 months of age. However, at 12 months the majority of GHR(-/-), hGHRH pituitaries developed adenomas with mean pituitary weight and histological features similar to those of GHR(+), hGHRH mice. These observations demonstrate that intact GH signaling is not required for GHRH tumor formation. Although the majority of GHR(+), hGHRH and GHR(-/-), hGHRH pituitaries developed tumors by 12 months of age, a small subset remained morphologically indistinct from those at 2 months of age. These observations taken together with the fact that overt tumor formation is preceded by a static pituitary growth phase between 2 and 6 months, indicates that protective mechanisms are in place to maintain pituitary mass despite hGHRH hyperstimulation.
在金属硫蛋白启动子驱动的人促生长激素释放激素(hGHRH)转基因小鼠中,过量的GHRH刺激会导致生长激素细胞增生,并最终形成垂体腺瘤。这种垂体表型与在异位产生GHRH的人类中观察到的表型相似。在小鼠和人类中,GHRH过度刺激还会导致循环中的生长激素(GH)和胰岛素样生长因子-I(IGF-I)显著增加。为了确定GH/IGF-I是否调节GHRH诱导的垂体肿瘤的发生和生长速度,我们对金属硫蛋白启动子驱动的hGHRH转基因小鼠与生长激素受体结合蛋白(GHR)基因敲除小鼠(GHR(-/-))杂交产生的小鼠的垂体生长和组织学进行了评估。在2个月大的GHR完整(GHR(+))小鼠中,hGHRH转基因的表达导致垂体重量增加一倍,这主要归因于GH免疫阳性细胞数量的增加。GHR(+) hGHRH小鼠的垂体重量在2至6个月龄之间没有显著变化,而在12个月时,重量增加至GHR(+)垂体的100倍,并且70%的腺体含有肉眼可见的腺瘤。所有腺瘤GH染色均为阳性,而一些显示散在的催乳素(PRL)染色。GHR(-/-)小鼠的垂体大小是GHR(+)小鼠的一半。尽管大小减小,但GHR(-/-)小鼠垂体的组织学特征提示生长激素细胞增生。尽管有生长激素细胞增生的证据,但28个月龄的GHR(-/-)小鼠的垂体大小与2个月龄小鼠的垂体大小相似,且未显示腺瘤形成的迹象。在2至6个月龄之间,hGHRH转基因在GHR(-/-)小鼠中的表达并未显著增加垂体大小。然而,在12个月时,大多数GHR(-/-)、hGHRH垂体形成了腺瘤,其平均垂体重量和组织学特征与GHR(+)、hGHRH小鼠相似。这些观察结果表明,GHRH肿瘤形成不需要完整的GH信号传导。尽管大多数GHR(+)、hGHRH和GHR(-/-)、hGHRH垂体在12个月龄时形成了肿瘤,但一小部分在形态上仍与2个月龄时的垂体无明显差异。这些观察结果与2至6个月之间垂体生长处于静止期后才出现明显肿瘤形成这一事实相结合,表明尽管存在hGHRH过度刺激,但仍有保护机制维持垂体质量。